FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, in particular to methods of using expression levels of one or more stromal signature genes as selection criteria for determining a patient suffering from cancer, which is resistant to chemotherapy, which can benefit from a specific anti-cancer therapy, such as a stroma-targeted therapy, an anti-angiogenic therapy and/or immunotherapy.
EFFECT: present invention also refers to methods of applying expression levels of one or more stromal signature genes as a selection criterion for treating patients with malignant growth, such as patients with ovarian cancer, using an agent aimed at stroma.
56 cl, 11 dwg, 11 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-ANGIOGENESIS THERAPY USED FOR TREATING BREAST CANCER | 2009 |
|
RU2531948C2 |
| ANTI-ANGIOGENESIS THERAPY FOR TREATING PREVIOUSLY TREATED BREAST CANCER | 2010 |
|
RU2576027C2 |
| DNA-VACCINE FOR APPLICATION IN PATIENTS WITH PANCREATIC CANCER | 2013 |
|
RU2636348C2 |
| DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA | 2014 |
|
RU2706968C2 |
| BIOMARKERS BASED ON TUMOR TISSUE FOR COMBINED THERAPY WITH BEVACIZUMAB | 2011 |
|
RU2605282C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| TREATMENT WITH ANTIBODIES AGAINST VEGF | 2004 |
|
RU2519669C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
| ANTI-VEGF ANTIBODIES AND APPLICATIONS THEREOF | 2010 |
|
RU2567639C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
